Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 5/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20424063 | 0.94 | LRRK2 (0.49) | LRRK2RXRARXRBRXRGCYP4F2 | |
| SCHEMBL21796742 | 0.87 | RXRA (0.41) | LRRK2RXRARXRBRXRGATR | |
| SCHEMBL22765293 | 0.86 | RXRA (0.43) | LRRK2RXRARXRBRXRGCYP4F2 | |
| SCHEMBL29538787 | 0.86 | RXRA (0.43) | LRRK2RXRARXRBRXRGCYP4F2 | |
| SCHEMBL22749867 | 0.85 | LRRK2 (0.40) | LRRK2RXRARXRBRXRGDGAT2 | |
| SCHEMBL22750191 | 0.82 | LRRK2 (0.54) | LRRK2RXRARXRBRXRGABCG2 | |
| SCHEMBL22749844 | 0.81 | RXRA (0.43) | LRRK2RXRARXRBRXRGATR | |
| SCHEMBL29796145 | 0.80 | GPR119 (0.42) | RXRARXRBRXRGLMNA | |
| SCHEMBL22749636 | 0.80 | GPR119 (0.42) | RXRARXRBRXRGLMNA | |
| SCHEMBL25340718 | 0.78 | ATR (0.44) | LRRK2RXRARXRBRXRGATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858367-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-10858367-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| WO-2018137593-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018137593-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858367-B2 | Compounds | LRRK2, PARK7, PINK1 | LRRK2 1/4885RXRA 4584/4885RXRB 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.